The published manuscript contained a typing error in the chapter ‘Wild-type transthyretin amyloidosis (ATTRwt)’, subchapter ‘Treatment’ (page 13 of the PDF version). It reads: Treatment with tafamidis 61 mg should be considered for patients with cardiac ATTRwt amyloidosis and dyspnea NYHA I-II. [IIa, B].
The correct wording is: Treatment with tafamidis 61 mg should be considered for patients with cardiac ATTRwt amyloidosis and dyspnea NYHA I-III. [IIa, B].
The error occured during manuscript editing and is not in the authors responsability. It has now been corrected online. We apologize to the authors and readers for this error.
Published under the copyright license CC BY-NC-SA: This license allows reusers to distribute, remix, adapt, and build upon the material in any medium or format for noncommercial purposes only, and only so long as attribution is given to the creator. If you remix, adapt, or build upon the material, you must license the modified material under identical terms.